Aehr Test Systems: Form 10-Q for the period ended Feb 28, 2023
Filed with the SEC on Apr 13, 2023 and accepted by EDGAR at Apr 13, 2023, 16:24 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-02-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-12-01 to 2023-02-28 | $17.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-06-01 to 2023-02-28 | $42.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-12-01 to 2023-02-28 | $8.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2022-06-01 to 2023-02-28 | $21.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-12-01 to 2023-02-28 | $8.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-06-01 to 2023-02-28 | $21.3m | us-gaap:GrossProfit |
| Research and development | 3 months2022-12-01 to 2023-02-28 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-06-01 to 2023-02-28 | $4.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-12-01 to 2023-02-28 | $3.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-06-01 to 2023-02-28 | $8.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-12-01 to 2023-02-28 | $3.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-06-01 to 2023-02-28 | $7.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-12-01 to 2023-02-28 | $17.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-06-01 to 2023-02-28 | $49.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-12-01 to 2023-02-28 | $4.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-06-01 to 2023-02-28 | $8.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-12-01 to 2023-02-28 | $0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-06-01 to 2023-02-28 | $0.29 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-12-01 to 2023-02-28 | $0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-06-01 to 2023-02-28 | $0.31 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-12-01 to 2023-02-28 | 29,373,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-06-01 to 2023-02-28 | 29,080,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-06-01 to 2023-02-28 | $4.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-06-01 to 2023-02-28 | $178.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-02-28 | $17.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-02-28 | $76.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-02-28 | $84.4m | us-gaap:Assets |
| Current liabilities | At period end2023-02-28 | $9.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-02-28 | $15.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-02-28 | $68.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001654954-23-004701. Last ingested by Listed: Oct 29, 2026, 18:22 ET. Listed shows no prices and gives no investment advice.